NASDAQ$ZLAB
Zai Lab Limited-ADR · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Zai Lab's financial performance and corporate advancements were detailed, showcasing substantial revenue growth and strategic pipeline developments.
Zai Lab reported a strong fourth quarter and full year 2024, marked by a 66% increase in Q4 revenue to $109.1 million and a 50% increase in full-year revenue to $399.0 million. The company saw a 45% decrease in loss from operations for the quarter and is targeting $2 billion in revenue by 2028 and profitability in Q4 2025.
- Total revenues grew 66% year-over-year for the fourth quarter of 2024, reaching $109.1 million.
- Loss from operations decreased 45% year-over-year for the fourth quarter of 2024, amounting to $67.9 million.
- VYVGART and VYVGART Hytrulo sales reached $30.0 million for the fourth quarter of 2024.
- Zai Lab anticipates total revenue to be between $560 million and $590 million for the full year 2025.
Headline financials
Revenue & EPS history
Zai Lab · Revenue · Quarterly
$109M
Revenue by segment
Zai Lab · $52M total across 3 segments · Q3 2023
- ZEJULA$41.6M+6.1%80.0%
- NUZYRA$5.5M+266.7%10.6%
- VYVGART franchise$4.9M—9.4%
Forward guidance
Zai Lab expects continued rigorous financial discipline and anticipates total revenue to be in the range of $560 million to $590 million for full-year 2025 and to achieve profitability on a non-GAAP basis in the fourth quarter of 2025.
Tailwinds
- Drive the ramp-up of VYVGART in gMG and VYVGART Hytrulo in gMG and CIDP through new patient acquisition and expansion of duration of treatment
- Maintain ZEJULA leadership position in ovarian cancer in China
- Prepare for launch of potential blockbuster products including bemarituzumab in gastric cancer and KarXT in schizophrenia
- Rapidly advance the global Phase 1 study for ZL-1310 (DLL3 ADC with global rights) in SCLC and explore its potential in other neuroendocrine tumors
- Advance other assets with global rights including ZL-6201 (LRRC15 ADC) and ZL-1503 (IL-13/IL-31R) into Phase 1 development
Headwinds
- Risks related to commercializing approved products.
- Risks associated with obtaining funding for operations and business initiatives.
- Uncertainties in clinical and pre-clinical development of product candidates.
- Potential adverse decisions by regulatory authorities regarding approvals of product candidates.
- Risks related to doing business in China.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-0.1%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-0.5%
Avg return
30 days after
45%
13 / 29 earnings
Positive
+26.0%
Q1 2024
Best reaction
-11.2%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.9% | -7.0% | -20.9% | |
| Q4 2025 | +1.7% | -8.6% | -7.2% | |
| Q3 2025 | -6.4% | -11.3% | -21.4% | |
| Q1 2025 | +2.5% | +0.9% | +34.4% | |
| Q4 2024 | -2.0% | -3.1% | +6.3% | |
| Q3 2024 | -3.7% | -13.0% | -14.1% | |
| Q2 2024 | -5.6% | -7.8% | +11.3% | |
| Q1 2024 | +26.0% | +29.0% | +19.9% | |
| Q4 2023 | -0.9% | +0.5% | -23.7% | |
| Q3 2023 | +7.4% | +0.9% | -1.5% | |
| Q2 2023 | -11.2% | -5.4% | +3.5% | |
| Q1 2023 | +1.4% | -9.3% | -24.2% | |
| Q4 2022 | -0.6% | +7.3% | -10.5% | |
| Q3 2022 | +1.9% | +23.9% | +18.7% | |
| Q2 2022 | -5.0% | -6.2% | -8.0% | |
| Q1 2022 | -2.1% | +30.0% | +5.6% | |
| Q4 2021 | -4.0% | -26.0% | -19.6% | |
| Q3 2021 | +0.7% | -2.3% | -22.3% | |
| Q2 2021 | +0.6% | +0.9% | +0.4% | |
| Q1 2021 | -5.1% | -3.3% | +8.3% | |
| Q4 2020 | +0.3% | -7.0% | -9.6% | |
| Q4 2019 | -1.4% | -2.7% | +17.0% | |
| Q1 2020 | -8.7% | +3.1% | +18.3% | |
| Q2 2019 | +4.3% | +4.1% | -4.0% | |
| Q1 2019 | +3.7% | +6.7% | -9.7% | |
| Q4 2018 | +10.4% | +10.4% | +1.6% | |
| Q3 2018 | +6.7% | +13.6% | +13.1% | |
| Q4 2017 | -5.3% | -8.8% | +22.8% | |
| Q3 2017 | -2.2% | -0.6% | +0.3% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro